Home self-administration of misoprostol for medical abortion up to 56 days' gestation.
OBJECTIVE
Studies from the USA have suggested the feasibility and acceptability of home medical abortion, however the issue has not been addressed in the UK. This study aimed to assess the feasibility, efficacy and acceptability of home self-administration of misoprostol for medical abortion up to 56 days' gestation.


METHODS
Mifepristone 200 mg was given orally in hospital under nursing supervision. Women were provided with misoprostol tablets 600 microg and advised to take them sublingually 36-48 hours later. The main outcome measures were (1) feasibility, assessed through successful completion of abortion at home without the need for hospital admission, (2) efficacy, assessed through complete uterine evacuation without the need for further medical or surgical intervention and (3) women's acceptability of the procedure as assessed by questionnaire.


RESULTS
A total of 49 women participated in this study. Of these, 48 women aborted at home while one opted to be admitted to hospital after receiving misoprostol at home. One woman underwent surgical evacuation 5 weeks following abortion for excessive bleeding and retained products of conception. A total of 43/44 (98%) women were satisfied with having the abortion at home. Side effects experienced by women included nausea [32/40 (80%], vomiting [17/41 (42%)], diarrhoea [17/41 (42%)], shivering [26/40 (65%)], tiredness [32/40 (80%)], headache [12/39 (31%)], hot flushes [14/40 (35%)], dizziness [24/39 (62%)] and unpleasant mouth taste [19/38 (50%)].


CONCLUSIONS
This study suggests the feasibility and acceptability of home self-administration of misoprostol for medical abortion up to 56 days' gestation. These findings need to be assessed in the context of a randomised trial.
Hamoda
Haitham
H
Department of Obstetrics and Gynaecology, University of Aberdeen, Aberdeen, UK. ogy262@abdn.ac.uk
Ashok
Premila W
PW
Flett
Gillian M M
GM
Templeton
Allan
A
D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use*; D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D005240:Feasibility Studies; D005260:Female; D005865:Gestational Age; D006801:Humans; D016595:Misoprostol / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011247:Pregnancy; D012646:Self Administration
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol